JP2012513209A - 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用 - Google Patents

腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用 Download PDF

Info

Publication number
JP2012513209A
JP2012513209A JP2011542856A JP2011542856A JP2012513209A JP 2012513209 A JP2012513209 A JP 2012513209A JP 2011542856 A JP2011542856 A JP 2011542856A JP 2011542856 A JP2011542856 A JP 2011542856A JP 2012513209 A JP2012513209 A JP 2012513209A
Authority
JP
Japan
Prior art keywords
cancer
cells
adenoviral vector
tumor
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011542856A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012513209A5 (enExample
Inventor
アクセリ ヘムミンキ
アンナ カネルヴァ
ヴィンチェンツォ チェルロ
サリ ペソネン
Original Assignee
オンコス セラピュティックス オサケ ユキチュア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20080671A external-priority patent/FI20080671A0/fi
Application filed by オンコス セラピュティックス オサケ ユキチュア filed Critical オンコス セラピュティックス オサケ ユキチュア
Publication of JP2012513209A publication Critical patent/JP2012513209A/ja
Publication of JP2012513209A5 publication Critical patent/JP2012513209A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011542856A 2008-12-22 2009-12-21 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用 Pending JP2012513209A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
FI20080671A FI20080671A0 (fi) 2008-12-22 2008-12-22 Onkolyyttiset virukset
FI20080671 2008-12-22
FI20095466 2009-04-27
FI20095466A FI121508B (fi) 2008-12-22 2009-04-27 Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
US58597109A 2009-09-29 2009-09-29
US12/585,971 2009-09-29
PCT/FI2009/051025 WO2010072900A1 (en) 2008-12-22 2009-12-21 Oncolytic adenoviral vectors and methods and uses related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015156226A Division JP6280084B2 (ja) 2008-12-22 2015-08-06 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用

Publications (2)

Publication Number Publication Date
JP2012513209A true JP2012513209A (ja) 2012-06-14
JP2012513209A5 JP2012513209A5 (enExample) 2014-11-27

Family

ID=44502296

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011542856A Pending JP2012513209A (ja) 2008-12-22 2009-12-21 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用
JP2015156226A Expired - Fee Related JP6280084B2 (ja) 2008-12-22 2015-08-06 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015156226A Expired - Fee Related JP6280084B2 (ja) 2008-12-22 2015-08-06 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用

Country Status (20)

Country Link
EP (1) EP2379586B1 (enExample)
JP (2) JP2012513209A (enExample)
KR (1) KR101761094B1 (enExample)
CN (1) CN102264760B (enExample)
AU (1) AU2009332883B2 (enExample)
BR (1) BRPI0924123B8 (enExample)
CA (1) CA2748180C (enExample)
CY (1) CY1120039T1 (enExample)
DK (1) DK2379586T3 (enExample)
ES (1) ES2612889T3 (enExample)
HR (1) HRP20170165T1 (enExample)
HU (1) HUE031689T2 (enExample)
LT (1) LT2379586T (enExample)
PL (1) PL2379586T3 (enExample)
PT (1) PT2379586T (enExample)
RU (1) RU2520823C2 (enExample)
SG (1) SG173432A1 (enExample)
SI (1) SI2379586T1 (enExample)
WO (1) WO2010072900A1 (enExample)
ZA (1) ZA201104224B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522805A (ja) * 2013-04-18 2016-08-04 ティーアイエルティー・バイオセラピューティクス・オーワイＴＩＬＴ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 増強された養子細胞療法
JP2019509329A (ja) * 2016-01-15 2019-04-04 タルゴヴァックス オサケ ユキチュア がんを治療するためのアデノウイルス及び化学療法剤の組合せ
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070440A2 (en) 2009-12-10 2011-06-16 Ottawa Hospital Research Institute Oncolytic rhabdovirus
AU2011306846B2 (en) * 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
RU2013118723A (ru) * 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
US10238698B2 (en) 2012-01-25 2019-03-26 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
RU2019107976A (ru) 2013-02-21 2019-08-23 Тёрнстоун Лимитед Партнершип Композиция вакцины
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
EP3783032A1 (en) 2016-09-12 2021-02-24 Targovax Oy Combining adenovirus and checkpoint inhibitors for treating cancer
EP3534923A4 (en) 2016-11-01 2020-05-27 DNAtrix, Inc. COMBINATION THERAPY FOR THE TREATMENT OF BRAIN CARCINOMAS
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
WO2018127702A1 (en) 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
EP3610026B1 (en) 2017-04-14 2025-05-14 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
KR20240093758A (ko) 2017-04-21 2024-06-24 베이롤 칼리지 오브 메드신 종양용해성 바이러스요법 및 면역요법
CA3064897A1 (en) 2017-05-25 2018-11-29 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
EP3708657A4 (en) * 2017-11-08 2021-08-25 Kagoshima University ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) THAT IS CAPABLE OF TREATING METASTATIC CANCER ALSO WITH ENSURED SAFETY, WITH EXPRESSION CONTROL SYSTEM THAT BUILDS AN OPTIMAL EXPRESSION LEVEL
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
EP3725888A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase
EP3725323A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
EP3725322A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing granzyme and perforin
WO2021194183A1 (ko) * 2020-03-25 2021-09-30 ㈜큐리진 면역 회피성 항종양 아데노바이러스
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法
CN118853767A (zh) * 2024-08-22 2024-10-29 华中科技大学同济医学院附属同济医院 一种新型溶瘤腺病毒载体及其构建方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002538770A (ja) * 1998-11-10 2002-11-19 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ウイルスベクターとその製造及び投与の方法
JP2003501041A (ja) * 1999-06-01 2003-01-14 ユニバーシティ オブ ワシントン 細胞特異的な感染およびゲノム組み込みのためのキメラファイバータンパク質を発現する組換えアデノウイルスベクター
JP2003526377A (ja) * 2000-03-14 2003-09-09 ニユーロロジクス・インコーポレーテツド キメラキャプシドベクターの製造
WO2005030261A1 (en) * 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2276623B1 (es) * 2005-12-12 2008-06-01 Proyecto De Biomedicina Cima, S.L Nuevos adenovirus recombinantes de replicacion condicionada (crad).
WO2007103825A2 (en) 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Combination therapy with oncolytic adenovirus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002538770A (ja) * 1998-11-10 2002-11-19 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ウイルスベクターとその製造及び投与の方法
JP2003501041A (ja) * 1999-06-01 2003-01-14 ユニバーシティ オブ ワシントン 細胞特異的な感染およびゲノム組み込みのためのキメラファイバータンパク質を発現する組換えアデノウイルスベクター
JP2003526377A (ja) * 2000-03-14 2003-09-09 ニユーロロジクス・インコーポレーテツド キメラキャプシドベクターの製造
WO2005030261A1 (en) * 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANCER BIOLOGY & THERAPY, 2007, VOL.6, P.1726-1732, JPN6014022497, ISSN: 0002826056 *
CANCER GENE THERAPY, 2008.8(ONLINE), VOL.16, P.33-43, JPN6015013407, ISSN: 0003044397 *
CLIN. CANCER RES., 2008.4, VOL.14, NO.8, P.2450-2457, JPN6014022491, ISSN: 0002826053 *
J. VIROL., 1998, VOL.72, NO.12, P.9706-9713, JPN6014022495, ISSN: 0002826055 *
J. VIROL., 2002, VOL.76, NO.24, P.12775-12782, JPN6014022493, ISSN: 0002826054 *
MOLECULAR THERAPY, 2003, VOL.7, NO.6, P.755-764, JPN6015013405, ISSN: 0003044398 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522805A (ja) * 2013-04-18 2016-08-04 ティーアイエルティー・バイオセラピューティクス・オーワイＴＩＬＴ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 増強された養子細胞療法
JP2020011966A (ja) * 2013-04-18 2020-01-23 ティーアイエルティー・バイオセラピューティクス・オーワイＴＩＬＴ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 増強された養子細胞療法
US10647963B2 (en) 2013-04-18 2020-05-12 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US10787645B2 (en) 2013-04-18 2020-09-29 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
JP7114532B2 (ja) 2013-04-18 2022-08-08 ティーアイエルティー・バイオセラピューティクス・オーワイ 増強された養子細胞療法
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
JP2019509329A (ja) * 2016-01-15 2019-04-04 タルゴヴァックス オサケ ユキチュア がんを治療するためのアデノウイルス及び化学療法剤の組合せ
JP2022023978A (ja) * 2016-01-15 2022-02-08 タルゴヴァックス オサケ ユキチュア がんを治療するためのアデノウイルス及び化学療法剤の組合せ

Also Published As

Publication number Publication date
KR20110096579A (ko) 2011-08-30
CN102264760A (zh) 2011-11-30
ES2612889T3 (es) 2017-05-19
PL2379586T3 (pl) 2017-08-31
EP2379586B1 (en) 2016-11-02
DK2379586T3 (en) 2017-02-06
AU2009332883A1 (en) 2011-07-07
CA2748180C (en) 2017-06-20
RU2011130511A (ru) 2013-01-27
CN102264760B (zh) 2017-03-22
EP2379586A1 (en) 2011-10-26
CY1120039T1 (el) 2018-12-12
LT2379586T (lt) 2017-03-10
PT2379586T (pt) 2017-02-09
HUE031689T2 (en) 2017-07-28
KR101761094B1 (ko) 2017-08-04
HRP20170165T1 (hr) 2017-04-07
AU2009332883B2 (en) 2015-05-21
RU2520823C2 (ru) 2014-06-27
JP2016019530A (ja) 2016-02-04
SI2379586T1 (sl) 2017-02-28
SG173432A1 (en) 2011-09-29
WO2010072900A1 (en) 2010-07-01
JP6280084B2 (ja) 2018-02-14
CA2748180A1 (en) 2010-07-01
ZA201104224B (en) 2012-09-26
BRPI0924123B8 (pt) 2021-05-25
BRPI0924123B1 (pt) 2020-10-20

Similar Documents

Publication Publication Date Title
EP2379586B1 (en) Oncolytic adenoviral vectors and methods and uses related thereto
US9345787B2 (en) Adenoviral vectors and methods and uses related thereto
FI123955B (en) Oncolytic adenovirus
AU2011306845B2 (en) Oncolytic adenoviral vectors coding for monoclonal anti - CTLA - 4 antibodies
CN103221423B (zh) 溶瘤腺病毒载体及与其相关的方法和用途
FI121574B (fi) Ei-Ad5 adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
FI121508B (fi) Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
HK1161279A (en) Oncolytic adenoviral vetctors and methods and uses related thereto
HK1161279B (en) Oncolytic adenoviral vetctors and methods and uses related thereto
FI124926B (fi) Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140902

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140909

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20141006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150406